Evaluation of taranabant (MK-0364) for its self-administration in rhesus monkeys and for its discriminative stimulus effects in rats

Drug Development Research

Volumn 70, Issue 8, 2009, Pages 577-584

  Beardsley, Patrick M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Discrimination; MK 0364; Self administration; Taranabant

Indexed keywords

COCAINE; DRONABINOL; TARANABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; RAT; RHESUS MONKEY;

EID: 74549221390     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20336     Document Type: Article

References (22)

1. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, and others. 2008. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78.
2. Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, Soubrie P. 1999. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91:607-620.
3. Anonymous. 2007. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo. Prescrire Int 16:250.
4. Ator NA, Griffiths RR. 2003. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70(Suppl 3):S55-S72.
5. Balster RL. 1991. Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
6. Beardsley PM, Thomas BF. 2005. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 16:275-296.
7. Beardsley PM, Hayes BA, Balster RL. 1990. The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252:953-959.
8. Beardsley PM, Dance ME, Balster RL, Munzar P. 2002. Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. Eur J Pharmacol 435:209-216.
9. Cahill K, Ussher M. 2007. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (4):CD005353.
10. Chaperon F, Soubrie P, Puech AJ, Thiebot MH. 1998. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135:324-332.
11. Cheer JF, Kendall DA, Marsden CA. 2000. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) 151:25-30.
12. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. 2007. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713.
13. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. 1998. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
14. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza Jr TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X,Wang J, Xu SS, Francis B, Strack AM,MacIntyre DE, Shearman LP. 2007. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy] propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321:1013-1022.
15. Griffiths RR, Brady JV, Bradford LD. 1979. Predicting the abuse liability of drugs with animal drug self-administreation procedures: psychomotor stimulants and hallucinogens. In: Thompson T, Dews P, editors. Advances in behavioral pharmacology. New York: Academic Press.
16. Johanson CE, Balster RL. 1978. A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 30:43-54.
17. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, and others. 2004. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47:627-643.
18. Masserano JM, Karoum F, Wyatt RJ. 1999. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol 10:429-432.
19. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, and others. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
20. Santucci V, Storme JJ, Soubrie P, Le Fur G. 1996. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:PL103-PL110.
21. Sanudo-Pena MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. 1997. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 223:125-128.
22. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG. 2001. The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426:R3-R4.